Mostrando 9 resultados de: 9
Filtros aplicados
Publisher
American Journal of Therapeutics(7)
International Journal of Molecular Sciences(1)
Journal of Diabetes Research(1)
Área temáticas
Enfermedades(8)
Farmacología y terapéutica(5)
Medicina forense; incidencia de enfermedades(1)
Salud y seguridad personal(1)
An elevated level of physical activity is associated with normal lipoprotein(a) levels in individuals from Maracaibo, Venezuela
ArticleAbstract: Coronary artery disease is the main cause of death worldwide. Lipoprotein(a) [Lp(a)], is an independPalabras claves:Cardiovascular Risk, Lifestyle, lipoprotein(a), Physical activityAutores:Acosta L., Añez-Ramos R., Aparicio D., Arráiz N., Cano R.A., Cano-Ponce C., Colmenares C., Faria J., Finol F., Mengual-Moreno E., Peñaranda L., Pineda C., Rodriguez D., Rojas E.R., Rojas-Quintero J., Sanchez W., Sorell L.T., Toledo A.C., Urribarí J., Valmore Bermúdez, Velasco M.Fuentes:scopusEffect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects
ArticleAbstract: Dopamine agonists play an important role in the regulation of the central nervous-cardiovascular, rePalabras claves:dopamine, Dopaminergic agonists, Dopaminergic receptors, Hypertension, Insulin, Type 2 Diabetes mellitusAutores:Bolívar H., Cano R.A., Contreras F., Foullioux C., Lares M., Leal E.M., Maroun C., Pacheco B., Valmore Bermúdez, Velasco M.Fuentes:scopusEffects of metoclopramide and metoclopramide/dopamine on blood pressure and insulin release in normotensive, hypertensive, and type 2 diabetic subjects
ArticleAbstract: The objective is to determine cardiovascular and insulin release effects under metoclopramide (MTC)Palabras claves:dopamine, Dopamine receptors, Hypertension, Insulin release, Metoclopramide, Type 2 DiabetesAutores:Bolívar H., Cano R.A., Contreras F., Fouillioux C., González M.C., Hernández-Hernandez R., Lares M., Valmore Bermúdez, Velasco M.Fuentes:scopusHaemodynamical variables versus endothelial hormones in hypertensive and type 2 diabetic patients with endothelial dysfunction
ArticleAbstract: Leptin is a 167 aminoacid peptidic hormone secreted by adipose tissue. It works mainly in the hypothPalabras claves:C reactive protein, Hypertension, leptin, Nitric oxide, Type 2 Diabetes mellitusAutores:Cano R.A., Contreras F., Fouillioux C., González M.C., Gotera D., Lares M., Magaldi L., Mayda C.L., Pacheco B., Rojas-Quintero J., Valmore Bermúdez, Velasco M.Fuentes:scopusHomeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes
ArticleAbstract: Type 2 diabetes mellitus is a metabolic disorder that results from defects in both insulin secretionPalabras claves:Free fatty acids, HOMA, Insulin, Insulin Resistance, Type 2 Diabetes mellitusAutores:Acosta K., Aparicio D., Arráiz N., Bermúdez F.A., Briceño C., Bustamante M., Cabrera M., Cano R.A., Cano-Ponce C., Gómez J., Hernández-Hernandez R., Joselyn Zula, Leal E.M., Manuel V., Mengual-Moreno E., Rodriguez M., Valdelamar L., Valmore BermúdezFuentes:googlescopusMetabolic and hemodynamic markers of endothelial dysfunction in patients with hypertension and patients with type 2 diabetes during the cold pressor test
ArticleAbstract: Leptin, a 167-amino acid peptidic hormone secreted by adipose tissue, acts mainly in the arcuate hypPalabras claves:C-Reactive protein, Hypertension, leptin, Nitric oxide, Type 2 DiabetesAutores:Arráiz N., Cano R.A., Contreras F., Fouillioux C., Lares M., Leal E.M., Valmore Bermúdez, Velasco M.Fuentes:scopusMetformin plus low-dose glimeperide significantly improves homeostasis model assessment for insulin resistance (HOMA<inf>IR</inf>) and β-cell function (HOMA<inf>β-cell</inf>) without hyperinsulinemia in patients with type 2 diabetes mellitus
Conference ObjectAbstract: OBJECTIVE: Type 2 diabetes mellitus is characterized by insulin resistance and defects in insulin sePalabras claves:Glimeperide, HOMA, Homeostasis model assessment, Insulin Resistance, Metformin, Type 2 Diabetes mellitus, β-cell functionAutores:Bermúdez-Arias F., Cano R.A., Cano-Ponce C., Ciscek A., Contreras F., Hernández-Hernandez R., Israili Z.H., Leal E.M., Lemus M.A., Medina M.T., Seyfi H.A., Souki-Rincón A., Valasco M., Valmore BermúdezFuentes:scopusVariations of lipoprotein(a) levels in the metabolic syndrome: A report from the Maracaibo City metabolic syndrome prevalence study
ArticleAbstract: Background. Lipoprotein(a) [Lp(a)] is a known risk factor for cardiovascular disease, yet its influePalabras claves:Autores:Aguirre M.A., Añez-Ramos R., Bello L.M., Cabrera M., Cano R.A., Cano-Ponce C., Chávez-Castillo M., González M.C., Lubo A., Martínez M.S., Mejías J.C., Mengual-Moreno E., Montiel M., París R., Quevedo A., Rojas L., Rojas-Quintero J., Salazar-Vílchez J., Sánchez De Rosales M., Toledo A.C., Torres W., Torres Y., Valmore Bermúdez, Villalobos M.Fuentes:scopusRole of endocrine-disrupting chemicals in the pathogenesis of non-alcoholic fatty liver disease: A comprehensive review
ReviewAbstract: Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disorder, affecting arPalabras claves:Endocrine-disrupting chemicals, Environmental pollutants, Exposure, Liver disorder, Non-alcoholic fatty liver diseaseAutores:Cano G., Cano R.A., Dávila L.C.A., Diaz M.P., Gomez Y., González M.C., Manzano A., Ortega A., Parra H., Pérez J.L., Rojas-Quintero J., Valero-Cedeño N.J., Valmore Bermúdez, Veliz T.Fuentes:scopus